Dbv Technologies SA (DBV) dividends
DBV on Euronext Paris, ISIN FR0010417345, Health Care
Sign in to get an email when it declares a dividend.
Dbv Technologies SA dividend: key facts
Own Dbv Technologies SA? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next DBV dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Euronext Paris in EUR. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
| Year to | Revenue | Net income | EPS | Free cash flow | Source |
|---|---|---|---|---|---|
| 31 Dec 2025IFRS EUR | — | -€147.2m | -€1.05 | — | Source (opens in a new tab) |
| 31 Dec 2024IFRS EUR | €0 | -€114.1m | -€1.18 | — | Source (opens in a new tab) |
| 31 Dec 2023IFRS EUR | €0 | -€72.7m | -€0.76 | -€78.3mDerived | Source (opens in a new tab) |
About Dbv Technologies SA
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
From Wikipedia, CC BY-SA 4.0.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years12 Nov 2026 · AMF Info-Financière
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.